| 期 |
栏目 |
标题 |
文件 |
| 卷 79, 编号 9 (2004) |
Editorial |
Effects of carvedilol, atenolol and their combination with fosinopril on cardiac rhythm variability, clinicofunctional status and quality of life in patients with postinfarction left ventricular dysfunction |
|
| 卷 80, 编号 12 (2008) |
Editorial |
Clinico-immunological disorders in patients with ischemic heart disease and metabolic syndrome: correction with nebivolol |
|
| 卷 81, 编号 2 (2009) |
Editorial |
Combined antihypertensive treatment in hypertensive patients and type 2 diabetes mellitus |
|
| 卷 81, 编号 3 (2009) |
Editorial |
Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus |
|
| 卷 81, 编号 5 (2009) |
Editorial |
Long-term results of coronary endovascular revascularisation with eluting sirolimus-stents in patients with coronary heart disease comorbid with type-2 diabetes mellitus: evidence from 18-month prospective study |
|
| 卷 84, 编号 12 (2012) |
Editorial |
Quality of life in patients with coronary heart disease associated with metabolic syndrome: Results of factor analysis |
|
| 卷 85, 编号 1 (2013) |
Editorial |
Impact of angiotensionogen and angiotensin II receptor type 1 gene polymorphisms on the development and course of chronic heart failure |
|
| 卷 85, 编号 5 (2013) |
Editorial |
Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome |
|
| 卷 87, 编号 4 (2015) |
Editorial |
Assessment of the role of matrix metalloproteinase-2 gene polymorphism in the development of chronic heart failure |
|
| 卷 88, 编号 9 (2016) |
Editorial |
Role of soluble Fas ligand in myocardial remodeling, severity and outcomes of chronic heart failure |
(Rus)
|
